ClinicalTrials.gg
RecruitingNCT04347473Updated Apr 15, 2020

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

A Phase 4 interventional study of Ilumya Injectable Product in Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-15.

Sponsored by Psoriasis Treatment Center of Central New Jersey · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2020, 5 years 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2020; still recruiting 6 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing tildrakizumab in Psoriasis — 2 open to participants now, 4 under way, 2 of them phase 3. tildrakizumab · Psoriasis.

Planned enrollment
13th of 16
25 · median 117
Started
2020
with 6 others
Phase 4
8 of 16
2 open now
Registered
11th of 16
by date
Lead sponsor
1 of 16
Psoriasis Treatment Center of Central New Jersey

Among the 16 studies testing tildrakizumab in Psoriasis, this one is the 13th largest by planned enrollment, is one of 7 that started in 2020, is one of 8 in phase 4, and was the 11th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 16 studies testing tildrakizumab in Psoriasis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tildrakizumab

tildrakizumab: first FDA approval 2018 (ILUMYA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing tildrakizumab in Psoriasis, or all of them as a file.
02

Study summary

Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment.

Read the detailed description

25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg subcutaneously at weeks 0, 4 and 16.

At week 16, patients with remaining BSA ˃3% will be given HALOG ointment 0.1% to apply BID for 4 weeks. Patients who have ≤3% BSA at week 16 will remain on Ilumya monotherapy.

Patients will continue to be evaluated at weeks 20 and 24.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult ≥ 18 years of age;
  2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by

    • BSA 10%
    • PGA ≥3
    • PASI ≥12
  3. Must be a candidate for phototherapy and/or systemic therapy
  4. Females of (FCBP) must have a negative serum pregnancy test at Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity in which conception is possible must use one of the approved options: hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's vasectomy; Male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide.

Exclusion criteria

Exclusion Criteria:

  1. Non-plaque forms of psoriasis
  2. Women of who are pregnant, intend to become pregnant, or are lactating
  3. Presence of significant uncontrolled medical condition that in the opinion of the investigator would affect patient safety during the trial.
  4. Active or untreated latent tuberculosis (TB)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Ilumya

    Ilumya 100mg subcutaneous at weeks 0, 4 and 16.

    Drug: Ilumya Injectable Product

Interventions

06

What researchers measure

Primary outcomes

  1. Body surface area

    evaluation of body surface area percentage affected by psoriasis where 1 palm is equivalent to 1%

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
    Recruiting
    • Elise Nelson · Contactenelson@windsordermatology.com · 609-443-4500
    • Jerry Bagel, MD · Principal investigator
    • David Nieves, MD · Sub investigator
    • Alexa Hetzel, PA-C · Sub investigator
    • Brianna Butler, PA-C · Sub investigator
    • Wendy Myers, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Dec 2020, 8 months after the start.

Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 8 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2020
First posted
Apr 15, 2020
StartActual
Apr 6, 2020
Primary completionEst.
Dec 30, 2020
CompletionEst.
Mar 1, 2021
Last update
Apr 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04347473
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
Apr 6, 2020
Primary completion
Dec 30, 2020 (estimated)
Completion
Mar 1, 2021 (estimated)
Last update
Apr 15, 2020

Study contacts

Jerry Bagel, MD
Contact
dreamacres1@aol.com
6094434500
Elise Nelson
Contact
enelson@windsordermatology.com
6094434500

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tildrakizumab

Start the discussion